Retatrutide, an experimental weight-loss injection developed by pharmaceutical giant Eli Lilly, is attracting growing attention for its remarkable results and potential side effects.
Unlike existing treatments that target one or two hormone pathways, retatrutide acts on three receptors involved in appetite and metabolism. Clinical trials have demonstrated substantial weight reduction, with some participants losing more than a quarter of their body weight.
However, researchers have also reported adverse reactions, including nausea, vomiting, diarrhoea, constipation and increased heart rate. More recent studies have identified low blood pressure and unusual skin sensations among additional concerns.
Although the results suggest a potentially significant breakthrough in obesity treatment, experts emphasise that long-term safety remains under investigation. Retatrutide has not yet received FDA approval, and patients are being warned against purchasing unregulated versions online.
The treatment’s future will depend on further safety evaluation and regulatory review.